Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases

Surgery

Volumn 130, Issue 3, 2001, Pages 470-478

  Sabel, Michael S ^a,b   Hill, Hank ^a,b   Jong, Yong S ^a,b   Mathiowitz, Edith ^a,b   Bankert, Richard B ^a,b   Egilmez, Nejat K ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; MICROSPHERE; POLYLACTIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; LUNG METASTASIS; LUNG NODULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR IMMUNITY;

EID: 0034835216     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2001.115839     Document Type: Article

References (38)

1. Antitumor and antimetastatic activity of interleukin 12
2. Phase I evaluation of intravenous recombinant human interleukin-12 (rhIL-12) in patients with advanced malignancies
3. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma mad immunogenic by IL-12 gene transfection
4. Fibroblasts genetically engineered to secrete IL-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo
5. Controlled release biodegradable cytokine depots: A new approach in cancer vaccine design
6. Controlled release of interleukin-2 from biodegradable microspheres
7. Development of an interleukin-2 slow delivery system
8. Enhancement of therapeutic effects of recombinant interleukin-2 on a transplantable rat fibrosarcoma by the use of a sustained release vehicle, pluronic gel
9. Biologically erodable microspheres as potential oral drug delivery systems
10. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model
11. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID/Winn model
12. In situ tumor vaccination with interleukin-12 encapsulated biodegradable microspheres: Induction of tumor regression and potent antitumor immunity
13. A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor
14. Accurate identification of pulmonary metastases
15. The SCID mouse mutant: Definition characterization and potential uses
16. Selective long-term elimination of natural killer cells in vivo by an anti-interlettkin 2 receptor β chain monoclonal antibody in mice
17. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
18. Antitumor activity of interleukin 12 in preclinical models
19. Antitumor and antimetastatic effects of interleukin 12
20. In vivo therapeutic effects of interleukin 12 against highly metastatic residual lymphoma
21. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
22. Preclinical development of IL-12 as an anticancer drug; comparison to IL-2
23. Interleukin-12: A cytokine with therapeutic potential in oncology and infectious diseases
24. Effects of local cytokine therapy
25. Cancer immunotherapy of established tumors with IL-12: Effective delivery by genetically engineered fibroblasts
26. CD4 T cells inhibit in vivo the CD8 mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes
27. Clinical protocol: IL-12 gene therapy using direct injections of tumors with genetically engineered autologous fibroblasts
28. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biological therapy of patients with cancer
29. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy
30. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene
31. Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo
32. An adenoviral vector expressing interleukin 4 modulates tumorigenicity and induces regression in a murine breast cancer model
33. Adenovirus mediated IL-12 gene therapy for metastatic colon carcinoma
34. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: In vitro and in vivo production of biologically active IL-12
35. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer
36. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12
37. Antitumor efficacy of adenocarcinoma cells engineered to produce IL-12 or other cytokines compared with exogenous IL-12
38. Alteration of the metastatic potential of Line-1 lung carcinoma cells: Opposite effects of class I antigen induction by interferons versus DMSO or gene transfection